Skip to main content
Clinical Trials/NCT00147030
NCT00147030
Completed
Not Applicable

Whole Body Hypothermia for the Treatment of Perinatal Asphyxial Encephalopathy

Imperial College London1 site in 1 country325 target enrollmentDecember 2002

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Asphyxia Neonatorum
Sponsor
Imperial College London
Enrollment
325
Locations
1
Primary Endpoint
Combined Incidence of Mortality and Severe Neurodevelopmental Disability in Survivors
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Hypothesis: Prolonged whole body cooling in term infants with perinatal asphyxial encephalopathy reduces death and severe neurodevelopmental disability.

This study aims to determine whether whole body cooling to 33-34°C is a safe treatment that improves survival, without severe neurological or neurodevelopmental impairments at 18 months, of term infants suffering perinatal asphyxial encephalopathy.

Detailed Description

This is a multicentre prospective randomised controlled trial to determine whether a reduction of body temperature by 3-4°C following perinatal asphyxia improves survival without neurodevelopmental disability. Full term infants will be randomised within 6 hours of birth to either a control group with the rectal temperature kept at 37 ± 0.2°C or to whole body cooling with the rectal temperature kept at 33.5 ± 0.5°C for 72 hours followed by slow rewarming. The outcome will be assessed at 18 months of age by survival and neurological and neurodevelopmental testing. Eligibility criteria: Term infants less than 6 hours after birth with moderate or severe perinatal asphyxia (a combination of clinical and EEG criteria). Exclusion criteria: Infants expected to be 6 hours of age at the time of randomisation or infants with major congenital abnormalities. Intervention: Intensive care with whole body cooling versus intensive care without whole body cooling (babies are cooled to 33.5°C for 72 hours) Main Outcomes: Death and severe neurodevelopmental impairment at 18 months of age Secondary Outcomes: Cerebral thrombosis or haemorrhage, persistent hypotension, pulmonary hypertension, abnormal coagulation, arrhythmia and sepsis in the neonatal period. Neurological impairments at 18 months Number of patients required: 236. On 30th November 2006, when recruitment closed, 325 babies had been recruited.

Registry
clinicaltrials.gov
Start Date
December 2002
End Date
August 2008
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Combined Incidence of Mortality and Severe Neurodevelopmental Disability in Survivors

Time Frame: 18 months

Severe neurodevelopmental disability was defined as a score of less than 70 on the Mental Developmental Index of the Bayley Scales of Infant Development II (BSID-II) (on which the standardization mean \[± standard deviation (SD)\] is 100±15 and higher scores indicate better performance), a score of 3 to 5 on the Gross Motor Function Classification System (GMFCS) (on which scores can range from 1 to 5, with higher scores indicating greater impairment), or bilateral cortical visual impairment with no useful vision.

Secondary Outcomes

  • Mortality(18 months)
  • Culture Proven Sepsis(Duration of hospital stay, on average 22 days)
  • Major Venous Thrombosis(Duration of hospital stay, on average 22 days)
  • Sensorineural Hearing Loss(18 months)
  • Persistent Hypotension(Duration of hospital stay, on average 22 days)
  • Intracranial Haemorrhage(Duration of hospital stay, on average 22 days)
  • Pulmonary Hypertension(Duration of hospital stay, on average 22 days)
  • Prolonged Blood Coagulation Time(Duration of hospital stay, on average 22 days)
  • Necrotising Enterocolitis(Duration of hospital stay, on average 22 days)
  • Cardiac Arrhythmia(Duration of hospital stay, on average 22 days)
  • Thrombocytopenia(Duration of hospital stay, on average 22 days)
  • Pulmonary Haemorrhage(Duration of hospital stay, on average 22 days)
  • Epilepsy (Defined as Recurrent Seizures Beyond the Neonatal Period, Requiring Anticonvulsant Therapy at the Time of Assessment)(18 months)
  • Microcephaly(18 months)
  • Renal Failure Treated With Dialysis(Duration of hospital stay, on average 22 days)
  • Severe Neurodevelopmental Disability(18 months)
  • Pneumonia(Before discharge from hospital)
  • Pulmonary Airleak(Duration of hospital stay, on average 22 days)
  • Duration of Hospitalisation(Duration of hospital stay, on average 22 days)
  • Multiple Handicap(18 months)
  • Bayley Psychomotor Developmental Index Score (PDI)(18 months)

Study Sites (1)

Loading locations...

Similar Trials